Xuehai Liang

Dr. Xuehai Liang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
SCStanley T Crooke
Stanley T Crooke
SWShiyu Wang
Shiyu Wang
TVTimothy A Vickers
Timothy A Vickers
WSWen Shen
Wen Shen
XLXuehai Liang
Xuehai Liang

4 June 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SCStanley T. Crooke
Stanley T. Crooke
TVTimothy A Vickers
Timothy A Vickers
XLXuehai Liang
Xuehai Liang
Antisense oligonucleotides (ASOs) interact with target RNAs via hybridization to modulate gene expression through different mechanisms. ASO therapeutics are chemically modified and include phosphorothioate (PS) backbone modifications and different ribose and base modifications to improve pharmacological properties. Modified PS ASOs display better binding affinity to the target RNAs and increased binding to proteins. Moreover, PS ASO protein interactions can affect many aspects of their performance, including distribution and tissue delivery, cellular uptake, intracellular trafficking, potency and toxicity. In this review, we summarize recent progress in understanding PS ASO protein interactions, highlighting the proteins with which PS ASOs interact, the influence of PS ASO protein interactions on ASO performance, and the structure activity relationships of PS ASO modification and protein interactions. A detailed understanding of these interactions can aid in the design of safer and more potent ASO drugs, as illustrated by recent findings that altering ASO chemical modifications dramatically improves therapeutic index.

29 April 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
WSWen Shen
Wen Shen
CHCheryl L. De Hoyos
Cheryl L. De Hoyos
MMMichael T. Migawa
Michael T. Migawa
TVTimothy A. Vickers
Timothy A. Vickers
HSHong Sun
Hong Sun
SCStanley T. Crooke
Stanley T. Crooke

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SCStanley T. Crooke
Stanley T. Crooke
XLXuehai Liang
Xuehai Liang
BBBrenda F. Baker
Brenda F. Baker
RCRosanne M. Crooke
Rosanne M. Crooke
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA Targeted drugs including 8 single strand antisense drugs (ASOs) and 2 double strand ASOs (siRNAs) have now been approved for commercial use and the ASOs in Phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow and the field has been subject to a significant number of reviews. In this review, we focus on the molecular events that result in the effects observed and use recent clinical results involving several different ASOs to exemplify specific molecular mechanisms and specific issues. We conclude with the prospective on the technology.

1 September 2017 in Molecular Therapy
Verified
Journal Article
Open access
XLXuehai Liang
Xuehai Liang
HSHong Sun
Hong Sun
JNJoshua G. Nichols
Joshua G. Nichols
SCStanley T. Crooke
Stanley T. Crooke
RNase H1-dependent antisense oligonucleotides (ASOs) are active in reducing levels of both cytoplasmic mRNAs and nuclear retained RNAs. Although ASO activity in the nucleus has been well demonstrated, the cytoplasmic activity of ASOs is less clear. Using kinetic and subcellular fractionation studies, we evaluated ASO activity in the cytoplasm. Upon transfection, ASOs targeting exonic regions rapidly reduced cytoplasmically enriched mRNAs, whereas an intron-targeting ASO that only degrades the nuclear pre-mRNA reduced mRNA levels at a slower rate, similar to normal mRNA decay. Importantly, some exon-targeting ASOs can rapidly and vigorously reduce mRNA levels without decreasing pre-mRNA levels, suggesting that pre-existing cytoplasmic mRNAs can be cleaved by RNase H1-ASO treatment. In addition, we expressed a cytoplasm-localized mutant 7SL RNA that contains a partial U16 small nucleolar RNA (snoRNA) sequence. Treatment with an ASO simultaneously reduced both the nuclear U16 snoRNA and the cytoplasmic 7SL mutant RNA as early as 30 min after transfection in an RNase H1-dependent manner. Both the 5' and 3' cleavage products of the 7SL mutant RNA were accumulated in the cytoplasm. Together, these results demonstrate that RNase H1-dependent ASOs are robustly active in both the cytoplasm and nucleus.

20 August 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
BABrooke A Anderson
Brooke A Anderson
GFGraeme C Freestone
Graeme C Freestone
ALAudrey Low
Audrey Low
CDCheryl L De-Hoyos
Cheryl L De-Hoyos
WIWilliam J Drury Iii
William J Drury Iii
TPThazha Prakash
Thazha Prakash
The PS modification enhances the nuclease stability and protein binding properties of gapmer antisense oligonucleotides (ASOs) and is one of very few modifications that support RNaseH1 activity. We evaluated the effect of introducing stereorandom and chiral mesyl-phosphoramidate (MsPA) linkages in the DNA gap and flanks of gapmer PS ASOs and characterized the effect of these linkages on RNA-binding, nuclease stability, protein binding, pro-inflammatory profile, antisense activity and toxicity in cells and in mice. We show that all PS linkages in a gapmer ASO can be replaced with MsPA without compromising chemical stability and RNA binding affinity but these designs reduced activity. However, replacing up to 5 PS in the gap with MsPA was well tolerated and replacing specific PS linkages at appropriate locations was able to greatly reduce both immune stimulation and cytotoxicity. The improved nuclease stability of MsPA over PS translated to significant improvement in the duration of ASO action in mice which was comparable to that of enhanced stabilized siRNA designs. Our work highlights the combination of PS and MsPA linkages as a next generation chemical platform for identifying ASO drugs with improved potency and therapeutic index, reduced pro-inflammatory effects and extended duration of effect.